No. 83

ANS news

ANS approves new technologies for inclusion in the Rol

At a meeting on Jan 30, the Board of Directors (DICOL) of the National Supplementary Health Agency (ANS) approved the update of the guidelines for use (DUTs) of treatments for atopic dermatitis and severe hemophilia A, in order to add medicines to the List of Health Procedures and Events (Rol), expanding coverage for health plan beneficiaries. Thus, following the revision of the DUTs, coverage will be as follows:

DUT 158, “Outpatient Injectable Drug Therapy (with guideline for use)” – inclusion of the drug Metotrexto for the treatment of patients of any age with moderate to severe atopic dermatitis, as evidenced by one of the severity scales; and

DUT 65.18, “Intravenous, Intramuscular or Subcutaneous Immunobiological Therapy (with guideline for use)” – mandatory coverage of the drug Emicizumabe, for prophylactic treatment of patients with severe hemophilia A or with factor VIII activity level below 2%, without factor VIII inhibitor antibodies, aged up to 6 years at the start of treatment.

Medical care plans reach 53.2 million beneficiaries in December 2025

Dental-only segment reaches 35.5 million consumers

2nd Extraordinary Meeting of the Board of Directors (DICOL) of 2026

Items:

1) DIPRO ITEM – DECISION on the proposal to update the List of Health Procedures and Events (Rol). Preliminary Recommendation Technical Note – NTRP regarding UATs No. 186, 189 and 190. Opening of Public Consultation and Public Hearing. Proceeding No. 33910.000998/2026-86.

2) DIPRO ITEM – DECISION on the proposal to update the List of Health Procedures and Events (Rol). Return of the Public Consultation. Final Recommendation Technical Note – NTRF regarding UAT No. 172. Approval of the proposed Normative Resolution. Proceeding No. 33910.041022/2025-82.

3) DIPRO ITEM – DECISION on the proposal to suspend the deadline for completing the analysis regarding UAT No. 171. Inclisirana for the treatment of primary hypercholesterolemia or mixed dyslipidemia in patients with atherosclerotic disease. Proceeding No. 33910.048937/2025-19.